Biography

Prof. Dr. LIU Hui serves as the Director of the Pathology Department at the Affiliated Hospital of Xuzhou Medical University and the Director of the Pathology Teaching and Research Office at Xuzhou Medical University. She is also a leading member of multiple professional committees, including the Pathology Branch of the Jiangsu Provincial Medical Association and the Tumor Pathology Professional Committee of the Jiangsu Anti-Cancer Association. She received her Ph.D. from Nanjing Medical University and conducted research as a visiting scholar at the MD Anderson Cancer Center in the United States, focusing on lymphoma and clinical oncologic pathology.  She has published over 105 SCI papers, with more than 20 first or corresponding authorship papers in top academic journals such as Blood, American Journal of Surgical Pathology, Human Pathology, Histopathology, American Journal of Clinical Pathology, International Journal of Molecular Sciences, and American Journal of Hematology.

Publications

Representative publications:

1.Xiang C, Wu W, Fan M, Wang Z, Feng X, Liu C, Liu J, Liu G, Xia L, Si H, Gu Y, Liu N, Luo D, Wang Y, Ma D, Hu S and Liu H. Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS.   Front. Immunol. 2023,14:1132834.

2.Yu Ma, Sunkai Ling, Yuan Li, Mingyue Hu, Bo Kong, Peilin Huang, Hui Liu. Loss of heterozygosity for KrasG12D promotes malignant phenotype of pancreatic ductal adenocarcinoma by activating HIF-2α-c-Myc-regulated glutamine metabolism. Int J Mol Sci. 2022 Jun 15;23(12):6697. 

3.Dongshen Ma, Yuhan Ma, Yuanyuan Ma, Jia Liu, Ying Gu, Nian Liu, Chenxi Xiang, Hui Liu and Wei Sang. Molecular Subtyping of CD5+ Diffuse Large B-cell Lymphoma Based on DNA Targeted Sequencing and Lymph2Cx. Front Oncol. 2022 Aug 23;12:941347. doi: 10.3389/fonc.2022.941347. eCollection 2022.

4.Wei Sang, Yuhan Ma, Xiangmin Wang, et al. Clinicopathological features and genomic signature of de novo CD5-positive diffuse large B-cell lymphoma: A multicenter collaborative study.  Am J Surg Pathol. 2022 Nov 1;46(11):1533-1544. doi: 10.1097/PAS.0000000000001957. Epub 2022 Aug 26. (Communication)

5.Hui Liu, Zijun Y Xu-Monette, Guilin Tang, Wei Wang, Young Kim, Ji Yuan, Yu Li, Weina Chen, Yanping Li, George Y Fedoriw, Feng Zhu, Xiaosheng Fang, Catherine Luedke, L Jeffrey Medeiros, Ken H Young, Shimin Hu. EBV-positive high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology, 2022,8(3):575-588. doi: 10.1111/his.14585. 

6.Liu H, Shen Q, Chang C, et al. Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?  Front Oncol. 2021 Dec 23;11:795330.doi: 10.3389/fonc.2021.795330. eCollection 2021. 

7.Liu H, Hu S. EBV+ ALK+ large B-cell lymphoma.  Blood，2021,138 (25): 2741.

8.Chenxi Xiang, Huimin Ni, Zhina Wang, Binbin Ji, Bo Wang, Xiaoli Shi, Wanna Wu, Nian Liu, Ying Gu, Dongshen Ma, Hui Liu. Agent Repurposing for the Treatment of Advanced Stage Diffuse Large B-Cell Lymphoma Based on Gene Expression and Network Perturbation Analysis.  Front Genet. 2021,12:756784.

9.Liu H, Xiang C, Wu M, Hu S.  Follicular dendritic cell sarcoma with co-expression of CD4 and CD30 mimics anaplastic large cell lymphoma. Frontiers of oncology.  2020 May 29;10:876.

10.Liu H, Chen C, Ma D, Li Y, Yin Q, Li Q, Xiang C. Inhibition of PIM1 Attenuates the Stem Cell like Traits of Breast Cancer Cells by Promoting RUNX3 Nuclear Retention.   J Cell Mol Med. 2020 Jun;24(11):6308-6323. doi: 10.1111/jcmm.15272.

11.Liu H，Hu S. Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation. Blood 2020 Apr 23;135(17):1506. doi: 10.1182/blood.2020005039.

12.Liu H, Miao Y, Ferrajoli A, Tang G, McDonnell T, Medeiros LJ, Hu S. Leukemic Phase of Richter transformation: A Mimic of Acute Myeloid Leukemia that Responded to Ibrutinib Monotherapy. Am J Hematol. 2020 Oct;95(10):1221-1223.

13.Liu H, Yan Z, Yin Q, et al. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer. J Histochem Cytochem. 2018 Oct;66(10):709-721. doi: 10.1369/0022155418797315.